Difference between revisions of "Team:Macquarie Australia/Practices/Implementation/RiskAnalysis"

Identifying and managing risks

As with all commercial ventures it is imperative to understand the potential underlying risks that would impinge on the overall success of the business so that they can be effectively managed and potentially mitigated entirely. Typically risk falls under a few specific categories; financial, legal, market, technical and systematic. Ultimately the appraisal of risk forms the basis for venture capital and private equity funding where investors seek opportunities to diversify their portfolios based on their unique risk profile.

Financial Risks

One of the greatest challenges for any potential business is raising sufficient capital necessary for a business to gain the momentum that ultimately yields income. A fundamental aspect of this process involves ascertaining costs associated with production, labour and ultimately optimisation. What makes our case challenging is that, unlike conventional ventures, optimisation of production through adequate research and development is the foremost sunk cost. After the reward of this sunk cost is realised, labour costs will be significantly minimized, the principal financial risk herein is realising a return for this initial outlay. In light of this there is growing interest globally in socially responsible investment opportunities (see Table 1) which represent ethical investments that neither contribute negatively socially or environmentally and represented $21.4 Trillion at the end of 2014 rising $13.3 trillion over the last two years (KPMG, 2015). This provides a significant opportunity for future technology ventures which are traditionally high risk, high outlay and difficult to finance. Furthermore it proves a path for future product development and global market expansion in the future particularly where SIR is more prevalent (see Figure 2).

Legal Risks

As explored in competitive advantage based on our conversations with two independant patent lawyers we have a fair case for IP provided that our product is novel (which to the best of our ability it is) but is also innovative solving a problem in a unique way. A key risk could be the failure to crystalise adequate intellectual protection in time to reap the rewards of exclusive rights under the presence of aggressive competitors.

Market Risks

Within the timeframes involved in bringing our product to market it is important to consider both the variability of global energy prices and sustained decline of renewable energy costs. At the time of writing brent oil prices are quite low making direct competition with fossil fuels challenging, while falling costs of photovoltaic cells pose even stronger competition.

Technical Risks

By far the most challenging risk involved with our project are technical and can be better understood as the relationship between efficiency and yield. Ultimately, synthetic biology creates real world solutions from naturally occurring processes .As such, this is both the biggest source of risk but also the largest source of opportunity. In nature, H₂ is produced at low rates, due to the complex reaction system necessary to overcome high amounts of free energy, the water splitting reaction producing ΔG = 237 kj. However, within the literature (Hallenbeck, Abo-Hashesh & Bosh, 2012) hydrogenases can achieve yields of 0.1% representing 2.5-13 mls H₂ l^-1 h^-1 being consistent with our mathematical modelling projects of 10.7mls H₂ l^-1 h^-1. There is a risk in falling short of the efficiencies required in using the hydrogenase enzyme which in and of itself has its own advantages and disadvantages.

As a contingency plan for inadequate yields and efficiency resulting from proton/oxygen separation, development of an oxygen resistant hydrogenase enzyme could significantly improve hydrogen production, and may be explored in the future. Furthermore other possible hydrogenase enzymes could be explored relative to the literature, as is seen in table 1. Ultimately the versatility of our design and synthetic biology in general means that the future optimisation of the hydrogenases could improve yields and efficiencies even further in the future.